Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients.
|Numero di pagine||9|
|Rivista||Journal of Hepatology|
|Stato di pubblicazione||Pubblicato - 2014|
- Hepatocellular carcinoma
- Lead-time bias